Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Colorcon
Fish and Richardson
Cerilliant
Deloitte
Cantor Fitzgerald
Baxter
QuintilesIMS
Fuji
Boehringer Ingelheim

Generated: October 20, 2017

DrugPatentWatch Database Preview

Epi Hlth Company Profile

« Back to Dashboard

What is the competitive landscape for EPI HLTH, and when can generic versions of EPI HLTH drugs launch?

EPI HLTH has one approved drug.

There are three US patents protecting EPI HLTH drugs.

There are thirty-two patent family members on EPI HLTH drugs in twenty-four countries and two supplementary protection certificates in two countries.

Summary for Applicant: Epi Hlth

International Patents:32
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epi Hlth
SITAVIG
acyclovir
TABLET;BUCCAL203791-001Apr 12, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Epi Hlth
SITAVIG
acyclovir
TABLET;BUCCAL203791-001Apr 12, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Epi Hlth
SITAVIG
acyclovir
TABLET;BUCCAL203791-001Apr 12, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Epi Hlth

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,211,466Mucosal bioadhesive slow release carrier for delivering active principles► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Epi Hlth Drugs

Country Document Number Estimated Expiration
China101410092► Subscribe
Slovenia1998750► Subscribe
BrazilPI0709057► Subscribe
World Intellectual Property Organization (WIPO)2011070125► Subscribe
Australia2007231029► Subscribe
Serbia51342► Subscribe
Canada2782779► Subscribe
European Patent Office2335690► Subscribe
Austria446743► Subscribe
Germany602007002996► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Epi Hlth Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Baxter
McKinsey
Farmers Insurance
Fuji
Novartis
Julphar
Queensland Health
Fish and Richardson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot